133 related articles for article (PubMed ID: 29623996)
21. Leptomeningeal Carcinomatosis in Chronic Lymphocytic Leukemia: A Case Report and Review of the Literature.
Naydenov AV; Taylor LP
Oncologist; 2019 Sep; 24(9):1237-1245. PubMed ID: 30842245
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
[TBL] [Abstract][Full Text] [Related]
23. Comparable outcomes in chronic lymphocytic leukaemia (CLL) patients treated with reduced-dose ibrutinib: results from a multi-centre study.
Mato AR; Timlin C; Ujjani C; Skarbnik A; Howlett C; Banerjee R; Nabhan C; Schuster SJ
Br J Haematol; 2018 Apr; 181(2):259-261. PubMed ID: 28220935
[No Abstract] [Full Text] [Related]
24. Disseminated fusarium infection after ibrutinib therapy in chronic lymphocytic leukaemia.
Chan TS; Au-Yeung R; Chim CS; Wong SC; Kwong YL
Ann Hematol; 2017 May; 96(5):871-872. PubMed ID: 28184982
[No Abstract] [Full Text] [Related]
25. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
Jain P; Keating MJ; Wierda WG; Sivina M; Thompson PA; Ferrajoli A; Estrov Z; Kantarjian H; O'Brien S; Burger JA
Clin Cancer Res; 2017 May; 23(9):2154-2158. PubMed ID: 27797975
[No Abstract] [Full Text] [Related]
26. [Chronic lymphocytic leukemia].
Aoki S
Rinsho Ketsueki; 2014 Feb; 55(2):213-22. PubMed ID: 24598189
[No Abstract] [Full Text] [Related]
27. Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.
Molica S; Levato L; Mirabelli R
Leuk Lymphoma; 2016; 57(3):735-7. PubMed ID: 26337717
[No Abstract] [Full Text] [Related]
28. Single-agent ibrutinib in RESONATE-2™ and RESONATE™ versus treatments in the real-world PHEDRA databases for patients with chronic lymphocytic leukemia.
Salles G; Bachy E; Smolej L; Simkovic M; Baseggio L; Panovska A; Besson H; Healy N; Garside J; Iraqi W; Diels J; Pick-Lauer C; Spacek M; Urbanova R; Lysak D; Hermans R; Lundbom J; Callet-Bauchu E; Doubek M
Ann Hematol; 2019 Dec; 98(12):2749-2760. PubMed ID: 31745601
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
30. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
31. Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease-negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections - Results from a phase I study.
Winqvist M; Palma M; Heimersson K; Mellstedt H; Österborg A; Lundin J
Br J Haematol; 2018 Aug; 182(4):590-594. PubMed ID: 28677818
[No Abstract] [Full Text] [Related]
32. Autoimmune myelitis in a CLL patient undergoing treatment with ibrutinib.
Wanner D; Bohn JP; Rudzki J; Stockhammer G; Steurer M
Ann Hematol; 2019 Jan; 98(1):205-207. PubMed ID: 29804266
[No Abstract] [Full Text] [Related]
33. Dose-limiting stomatitis associated with ibrutinib therapy: a case series.
Vigarios E; Beylot-Barry M; Jegou MH; Oberic L; Ysebaert L; Sibaud V
Br J Haematol; 2019 May; 185(4):784-788. PubMed ID: 30408164
[No Abstract] [Full Text] [Related]
34. Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.
Sun C; Gao J; Couzens L; Tian X; Farooqui MZ; Eichelberger MC; Wiestner A
JAMA Oncol; 2016 Dec; 2(12):1656-1657. PubMed ID: 27533065
[No Abstract] [Full Text] [Related]
35. Ibrutinib continues to influence the therapeutic landscape of chronic lymphocytic leukemia: new data presented at ASCO 2017.
Molica S
BMC Med; 2017 Aug; 15(1):156. PubMed ID: 28810856
[TBL] [Abstract][Full Text] [Related]
36. Appendix 4: Chronic lymphocytic leukaemia: eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies).
ESMO Guidelines Committee
Ann Oncol; 2017 Jul; 28(suppl_4):iv149-iv152. PubMed ID: 28881925
[No Abstract] [Full Text] [Related]
37. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials.
O'Brien SM; Jaglowski S; Byrd JC; Bannerji R; Blum KA; Fox CP; Furman RR; Hillmen P; Kipps TJ; Montillo M; Sharman J; Suzuki S; James DF; Chu AD; Coutre SE
JAMA Oncol; 2018 May; 4(5):712-716. PubMed ID: 29470582
[TBL] [Abstract][Full Text] [Related]
39. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia.
Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P
Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533
[TBL] [Abstract][Full Text] [Related]
40. Combination of Targeted Drugs to Control Chronic Lymphocytic Leukemia: Harnessing the Power of New Monoclonal Antibodies in Combination With Ibrutinib.
Cramer P; Langerbeins P; Hallek M
Cancer J; 2016; 22(1):62-6. PubMed ID: 26841018
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]